About Kodiak Sciences Inc.
https://kodiak.comKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.
CEO
Victor Perlroth
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-02-23 | Forward | 5:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 95
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:17.31M
Value:$496.29M
BLACKROCK INC.
Shares:3.85M
Value:$110.29M
BLACKROCK, INC.
Shares:2.95M
Value:$84.64M
Summary
Showing Top 3 of 139
About Kodiak Sciences Inc.
https://kodiak.comKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $55.81M ▲ | $-61.46M ▼ | 0% | $-1.16 ▼ | $-54.92M ▼ |
| Q2-2025 | $0 | $48.97M ▼ | $-54.31M ▲ | 0% | $-1.03 ▲ | $-47.77M ▲ |
| Q1-2025 | $0 | $50.45M ▲ | $-57.46M ▼ | 0% | $-1.09 ▼ | $-50.73M ▼ |
| Q4-2024 | $0 | $39.5M ▼ | $-44.1M ▼ | 0% | $-0.84 | $-37.42M ▼ |
| Q3-2024 | $0 | $39.94M | $-43.95M | 0% | $-0.84 | $-37.25M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $72.04M ▼ | $218.07M ▼ | $194.38M ▲ | $23.69M ▼ |
| Q2-2025 | $104.17M ▼ | $256.73M ▼ | $186.44M ▼ | $70.29M ▼ |
| Q1-2025 | $138.85M ▼ | $297.91M ▼ | $189.07M ▲ | $108.84M ▼ |
| Q4-2024 | $168.07M ▼ | $335.58M ▼ | $185.29M ▼ | $150.29M ▼ |
| Q3-2024 | $197.86M | $372.67M | $187.3M | $185.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-61.46M ▼ | $-32.88M ▲ | $-60K ▲ | $813K ▲ | $-32.13M ▲ | $-32.94M ▲ |
| Q2-2025 | $-54.31M ▲ | $-34.67M ▼ | $-133K ▲ | $120K ▼ | $-34.69M ▼ | $-34.81M ▼ |
| Q1-2025 | $-57.46M ▼ | $-29.08M ▲ | $-270K ▼ | $124K ▼ | $-29.22M ▲ | $-29.35M ▲ |
| Q4-2024 | $-44.1M ▼ | $-30.07M ▼ | $-124K ▲ | $404K ▲ | $-29.79M ▼ | $-30.19M ▼ |
| Q3-2024 | $-43.95M | $-21.16M | $-205K | $0 | $-21.36M | $-21.36M |
CEO
Victor Perlroth
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-02-23 | Forward | 5:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 95
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:17.31M
Value:$496.29M
BLACKROCK INC.
Shares:3.85M
Value:$110.29M
BLACKROCK, INC.
Shares:2.95M
Value:$84.64M
Summary
Showing Top 3 of 139